Getinge AB (publ) (GNGBY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Getinge AB (publ) (GNGBY) with AI Score 47/100 (Weak). Getinge AB (publ) is a Swedish company providing equipment and solutions for healthcare facilities globally. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Getinge AB (publ) (GNGBY) Healthcare & Pipeline Overview
Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.
Investment Thesis
Getinge AB (publ) presents a notable research candidate due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 22.79 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $5.43 billion reflects Getinge's significant presence in the medical device industry.
- Profit margin of 6.5% indicates efficient operations and profitability.
- Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
- Dividend yield of 2.43% provides an income stream for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Focus on innovation
Weaknesses
- Exposure to currency fluctuations
- Dependence on healthcare spending
- Competition from larger medical device companies
- Potential for product recalls
Catalysts
- Ongoing: Increasing demand for healthcare solutions driven by an aging global population.
- Ongoing: Advancements in medical technology and innovation.
- Upcoming: Potential strategic acquisitions to expand product portfolio and market reach.
- Ongoing: Expansion in emerging markets with developing healthcare infrastructure.
- Ongoing: Development of integrated solutions combining hardware, software, and services.
Risks
- Potential: Currency fluctuations impacting revenue and profitability.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Competition from other medical device manufacturers.
- Potential: Product recalls or safety concerns.
- Potential: Economic downturns affecting healthcare spending.
Growth Opportunities
- Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
- Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
- Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
- Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
- Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.
Opportunities
- Expansion in emerging markets
- Development of integrated solutions
- Strategic acquisitions
- Increasing demand for bioprocessing solutions
Threats
- Changes in healthcare regulations
- Economic downturns
- Technological obsolescence
- Increased competition
Competitive Advantages
- Established brand reputation and long-standing relationships with customers.
- Extensive distribution network and global reach.
- Diversified product portfolio across multiple healthcare segments.
- Strong focus on innovation and research and development.
About GNGBY
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.
What They Do
- Provides equipment for operating rooms and intensive-care units.
- Offers sterilization solutions for healthcare facilities.
- Develops and manufactures bioprocessing systems for the life science industry.
- Provides surgical workflows solutions.
- Offers acute care therapies, including anesthesia and ventilation equipment.
- Provides sterile transfer systems and closure processing systems.
Business Model
- Sells medical devices and equipment to hospitals, clinics, and research institutions.
- Provides service and maintenance contracts for its equipment.
- Offers software solutions for managing surgical workflows and bioprocessing operations.
- Generates revenue through a network of proprietary sales companies, agents, and distributors.
Industry Context
Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.
Key Customers
- Hospitals and clinics
- Research institutions
- Pharmaceutical and biotechnology companies
- Sterilization departments
Financials
Chart & Info
Getinge AB (publ) (GNGBY) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Friday
· Jan 10, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Nov 26, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNGBY.
Price Targets
Wall Street price target analysis for GNGBY.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNGBY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). Prior to joining Getinge, he held various leadership positions at other companies in the healthcare and technology sectors. His experience includes roles in sales, marketing, and general management. Perjos has a strong track record of driving growth and improving operational efficiency.
Track Record: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business, expanding its presence in key markets, and investing in innovation. He has overseen the development and launch of new products and solutions, as well as strategic acquisitions to enhance the company's competitive position. His tenure has been marked by a commitment to improving patient outcomes and delivering value to shareholders.
Getinge AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. GNGBY represents shares of Getinge AB (publ), a Swedish company. As an ADR, GNGBY allows U.S. investors to invest in Getinge without the complexities of cross-border transactions. Dividends are converted to U.S. dollars before distribution.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: GNGB
GNGBY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Higher price volatility
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established operating history
- Reputable management team
- Audited financial statements (if available)
- Positive news coverage or industry recognition
- Clear business model and value proposition
What Investors Ask About Getinge AB (publ) (GNGBY)
What does Getinge AB (publ) do?
Getinge AB (publ) provides a wide array of medical technology solutions, focusing on equipment and systems for operating rooms, intensive care units, and sterilization departments. The company operates through three segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its products range from anesthesia machines and ventilators to bioprocessing equipment and surgical tables, serving hospitals, research institutions, and pharmaceutical companies globally. Getinge aims to improve patient outcomes and optimize healthcare processes through its innovative solutions.
What do analysts say about GNGBY stock?
Analyst consensus on GNGBY stock is pending, as AI analysis is not yet available. Investors should monitor analyst ratings and price targets for updates. Key valuation metrics to consider include the company's P/E ratio, dividend yield, and growth prospects. Factors influencing analyst opinions include Getinge's financial performance, market position, and industry trends. It is important to conduct independent research and consider multiple perspectives before making investment decisions.
What are the main risks for GNGBY?
GNGBY faces several risks, including currency fluctuations due to its global operations, which can impact revenue and profitability. Changes in healthcare regulations and reimbursement policies could also affect the demand for its products. Intense competition from other medical device manufacturers poses a threat to market share. Additionally, product recalls or safety concerns could damage the company's reputation and financial performance. Economic downturns may reduce healthcare spending, impacting Getinge's sales.
What are the key factors to evaluate for GNGBY?
Getinge AB (publ) (GNGBY) currently holds an AI score of 47/100, indicating low score. Key strength: Diversified product portfolio. Primary risk to monitor: Potential: Currency fluctuations impacting revenue and profitability.. This is not financial advice.
How frequently does GNGBY data refresh on this page?
GNGBY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNGBY's recent stock price performance?
Recent price movement in Getinge AB (publ) (GNGBY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNGBY overvalued or undervalued right now?
Determining whether Getinge AB (publ) (GNGBY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNGBY?
Before investing in Getinge AB (publ) (GNGBY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.